NVD-003 is under clinical development by Novadip Biosciences and currently in Phase II for Pseudarthrosis (Nonunion of Fracture/Pseudoarthrosis). According to GlobalData, Phase II drugs for Pseudarthrosis (Nonunion of Fracture/Pseudoarthrosis) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NVD-003 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NVD-003 overview

NVD-003 is under development for the treatment of bone reconstruction for the treatment of recalcitrant lower limb non-union and congenital pseudarthrosis of the tibia and other rare pediatric bone disorders. It is administered as implant. It comprises of bone forming cells derived from autologous stem cells, which are embedded in their self-secreted extracellular matrix together with added hydroxyapatite particles. It is being developed based on 3M3 platform.

Novadip Biosciences overview

Novadip Biosciences (Novadip) is a developer of cell-based therapies for hard and soft tissue. The company’s pipeline product includes NVD-003, NVD-X3, NVD-M2 and exosomes and others. Its product uses autologous adipose-derived mesenchymal stem cells, which offer a range of benefits such as minimally invasive isolation procedures and reduced risk of recipient immunisation and graft rejection. It develops therapies to treat patients with bone defects and bone diseases. Its products are also applied in other indications such as orthopedic surgery for trauma or tumor resection, neurosurgery for the spine, cranial and maxillofacial surgery, and osteonecrosis among others. Novadip is headquartered in Nivelles, Brabant Wallon, Belgium.

For a complete picture of NVD-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.